Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Erli Gu"'
Publikováno v:
Cell Death Discovery, Vol 9, Iss 1, Pp 1-14 (2023)
Abstract Interleukin-35 (IL-35)-producing B cells (IL-35+B cells) play an important role in diseases, and the expansion of IL-35+ immune cells have been observed in inflammatory bowel disease (IBD). However, how IL-35+B cells function and the manner
Externí odkaz:
https://doaj.org/article/f9f9aab0e0fa44bdba79ea978f7115d3
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)
Abstract Background Stomach cancer (SC) is a type of cancer, which is derived from the stomach mucous membrane. As there are non-specific symptoms or no noticeable symptoms observed at the early stage, newly diagnosed SC cases usually reach an advanc
Externí odkaz:
https://doaj.org/article/b5aafad4f14d440f911e566339b6065c
Publikováno v:
European Journal of Gastroenterology & Hepatology. 34:546-552
Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world. The development of chronic hepatitis B (CHB)-related HCC can be attributed to continuous hepatitis B virus (HBV) infection. It is crucial to identify and monitor patients wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b3b3d49c021bc10d87f31ce17c36358
https://doi.org/10.1097/meg.0000000000002302
https://doi.org/10.1097/meg.0000000000002302
Autor:
Zhiyuan Gao, Hong Wang, Jun Ji, Erli Gu, Mengmeng Wang, Chenjun Huang, Ya Li, Xiao Xiao, Lijuan Liu, Chunfang Gao, Meng Fang
Publikováno v:
Liver International. 42:210-223
BACKGROUND GALAD is an algorithm model estimating the presence of hepatocellular carcinoma (HCC). However, the participants enrolled in the GALAD differ from those of Chinese subjects whose HCCs are mainly hepatitis B virus infection related. Therefo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9cc0919f5e97c594b5741245215b8e8
https://doi.org/10.1111/liv.15082
https://doi.org/10.1111/liv.15082
Publikováno v:
Pharmaceutical Care and Research. 21:189-199
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::93d5989d588c136ae1c1df7f26bf9b8a
https://doi.org/10.5428/pcar20210307
https://doi.org/10.5428/pcar20210307
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)
BMC Cancer
BMC Cancer
Background Stomach cancer (SC) is a type of cancer, which is derived from the stomach mucous membrane. As there are non-specific symptoms or no noticeable symptoms observed at the early stage, newly diagnosed SC cases usually reach an advanced stage
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be27201226b2c2081a7ffcf36e5ba693
http://link.springer.com/article/10.1186/s12885-020-06869-3
http://link.springer.com/article/10.1186/s12885-020-06869-3
Publikováno v:
BIO Web of Conferences, Vol 8, p 01029 (2017)
Objective: To objectively evaluate the clinical efficacy of Longchai Formula Granule (LCFG) on chronic hepatitis B (CHB). Methods: According to GCP, 100 CHB patients who meet enter criterion were encoded and divided randomly into the test group (50 c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac66fbebd9e63aa0adf686a052122b0e
https://doi.org/10.1051/bioconf/20170801029
https://doi.org/10.1051/bioconf/20170801029
Publikováno v:
Molecular Medicine Reports
Virological breakthrough is a clinical manifestation in patients infected with chronic hepatitis B (CHB), who undergo treatment with nucleoside/nucleotide analogs (NUCs). The current understanding of the underlying mechanism of virological breakthrou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86ace58d8f53ac5942b3d35e822af7f9
https://pubmed.ncbi.nlm.nih.gov/26648309
https://pubmed.ncbi.nlm.nih.gov/26648309
Autor:
Yanyan Ji, Hong-Ying Pan, Yi-Qi Yu, Wenhong Zhang, Yue-Er Wang, Xiao-Wei Xu, Hong Wang, Jiali Wang, Shan-Min Wu, Jun Li, Xiu-Yun Ma, Erli Gu, Guang-Bi Yao, Qing Xie, Cheng-Wei Chen
Publikováno v:
World journal of gastroenterology. 21(2)
To observe the effect of response-guided add-on therapy with adefovir (ADV) and lamivudine (LAM) in cirrhotic hepatitis B (CHB) patients.A total of 100 patients with CHB and cirrhosis were divided into three arms according to hepatitis B virus (HBV)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51769fbe1e69c1edd60a6c0cb5a82c4d
https://pubmed.ncbi.nlm.nih.gov/25605989
https://pubmed.ncbi.nlm.nih.gov/25605989
Publikováno v:
BIO Web of Conferences; 2017, Vol. 8, p1-8, 8p, 6 Charts